INVESTOR

PRESENTATION
March 2021

1
DISCLAIMER
The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by
you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on
or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable,
the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on,
the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any
responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any
other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or
otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to
be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.
The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements
contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to
provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form
part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiary or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this
document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the
market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal,
tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an
informed decision.
This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and
information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognised by the use of words such as “expects”,
“plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking
statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any
responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements,
which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any
responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding
off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.
This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the
markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally
state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have
independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited
and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.
The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.
This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it
form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies
Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of
securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.
By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have
jurisdiction over the same.
2
KEY HIGHLIGHTS

Leading private sector Attractive industry

01 healthcare services
provider 02 opportunity

Superior operating &

03 Excellence in practice 04 financial track record

Strong management Strategy for future

05 team 06 growth

3
 LEADING PRIVATE SECTOR
01 HEALTHCARE SERVICES
PROVIDER

4
 BUSINESS AT A GLANCE
Data as of Mar 31, 2021

1
Healthcare 50% 71 10,209 55% 4.19 days INR 40,214 / 352,000+ 4,200,000+
Services of revenue Hospitals Beds Occupancy ALOS3 day In-patients Out-patients
rates2 ARPOB4

Apollo 1

Health and 6%
Of revenue 4,118 INR 11.8mm 9.95%
Lifestyle Outlets Revenue / store Private label sales

1
Pharmacy 44% 191 22 796 62 69 15* 9* 11
platform Of revenue
Clinics Clinics Centers Centers Centers Centers Centers Centers

Apollo 24x7 6.6mm+ ~5,500+ ~2.9 lakhs

Registered users Doctors Online consults
completed
Revenue5 FY21: INR 105bn EBITDA6 FY21: INR 11bn
Note: 1 Including proforma for Apollo Gleneagles Hospital Limited, Kolkata (50% holding ; 100% subsidiary from Q1 FY22), Delhi (22% holding) & Medics International Life Sciences Limited (50% holding; 51% Subsidiary from Q4FY21) whose Revenues are not consolidated under Ind
AS due to joint control; 2Calculated as Total occupied bed days / total operating bed days for owned hospitals; 3 ALOS: Average length of stay in hospitals; 4ARPOB: Average revenue per occupied bed excluding fees paid to fee-for-service consultants; 5 Financials prior to
5
reorganization of Standalone Pharmacy business upto Aug 31st 2021. As part of reorganization, company divested its interest in front-end portion of stand-alone pharmacies business to Apollo Pharmacies Ltd, of which they own 25.5% through its associate, Apollo Medicals Private
Limited and remaining interest is held by 3 other investors , 6EBITDA is Post IND-AS 116. *Includes BOMA (Brand Operations and Management Agreement) Apollo Spectra (4) and Apollo Cradle & Children’s Hospital (1).
LARGEST PRIVATE HEALTHCARE SERVICES PROVIDER IN INDIA
Leading player in India in terms of number of hospitals
1
71

26 25
21
16 14 13 11 11 10
6

Fortis Healthcare Healthcare Global Narayana Max Healthcare Aster DM Care Hospitals Columbia Asia Shalby Ltd Manipal Hospitals Sterling Hospitals
Ltd Enterprises Ltd Hrudalaya Ltd Institute Ltd Healthcare Ltd Hospitals

Leading player in India in terms of number of beds available

10,209

6,725
5,310
3,757 3,400
2,675 2,182 2,036 2,012
1,259
568

Narayana Fortis Healthcare Aster DM Max Healthcare Manipal Hospitals Care Hospitals Healthcare Global Shalby Ltd Columbia Asia Sterling Hospitals
Hrudalaya Ltd Ltd Healthcare Ltd Institute Ltd Enterprises Ltd Hospitals

Note: Data as of Fiscal 2021; 1 Number of hospitals include only owned & managed hospitals . The numbers above exclude primary healthcare centers and clinics. Max Healthcare Institute includes beds in associate trust owned hospitals 6
PAN INDIA PRESENCE
Steadily increasing footprint supporting meaningful upside in future
71 hospitals present across India Healthy mix by category
Owned hospitals Day care centers / CRADLE Managed hospitals

5 851 851
542 542
Delhi: 5
Amritsar: 1 22 44
Noida: 1 71 10,209 8,930
8,816 7,409
Kanpur: 1 Bilaspur: 1
Lucknow: 1

Jaipur: 1
No. of Hospitals Capacity beds Operational beds

Ahmedabad: 2 Healthy mix by vintage (owned hospitals)

Guwahati: 1
Indore: 1 Mature hospitals1 New hospitals
Kolkata: 2
Nashik: 1 Pune: 2 Bhubaneshwar: 1
Mumbai: 3 Bacheli: 1
Karimnagar: 1 Vishakhapatnam: 2
Hyderabad: 9 2,862
Lavasa:1 Kakinada: 1 14 2,119
Nellore: 1
Aragonda: 1 44 8,816 5,954 7,409 5,290
30
Bangalore: 8 Chennai: 13
Mysore: 1 Ranipet: 1
Karur: 1
Madurai: 2
Overseas (Managed) Trichy: 1
Bahrain: 1 Karaikudi: 1 No. of Hospitals Capacity beds Operational beds
7
Note: Data as of Mar 31, 2021; 1Internally company classifies any hospital commissioned prior to 9 years as mature hospital
 LARGEST PHARMACY PLATFORM IN INDIA
Extensive Pharmacy network also supports the growth of Apollo 24X7 – Digital pharmacy platform
Largest pan-India pharmacy network Highly differentiated business model driving growth

Chandigarh: 6
Himachal Pradesh: 1
Uttarakhand: 6 Extensive Asset-light model Economies Data driven store
Punjab: 18 Assam: 6 distribution backend with high ROI of scale expansion
New Delhi: 114
Haryana: 79 Uttar Pradesh: 150
Bihar: 6
Rajasthan: 70

High customer 9.95% private Launched Omni-

Tripura: 3 retention labels sales channel online
Jharkhand: 8 platform “Apollo 24/7”

Gujarat: 181 West Bengal: 425 Highly strategic partnership with Pharmacy Platform
Orissa: 100
Maharashtra: 130 Chattisgarh: 34
Exclusive supplier to Apollo Pharmacy Ltd (25.5% stake)
Telangana: 655
Backend supply chain housed with AHEL
Goa: 19 Andaman: 2
Karnataka: 604 Andhra Pradesh: 634 Agreement to license “Apollo Pharmacy” brand
Puducherry: 17 Substantial majority of combined revenue & profits to be
Tamil Nadu: 850
captured in AHEL
8
Note: Data as of Mar 31, 2021 ; Total no of Pharmacies is 4,118 operated by Apollo Pharmacy Ltd (25.5% stake)
 ATTRACTIVE
02 INDUSTRY OPPORTUNITY

9
HUGELY UNDER-PENETRATED MARKET WITH ATTRACTIVE
DYNAMICS
Private sector players are well-positioned to leverage opportunity given low contribution of government spending
Growing Indian Healthcare Delivery industry Public healthcare expenditure is low, with private sector accounting for bulk
The healthcare delivery industry has grown at CAGR of 12-14% India Healthcare expenditure Out-of-pocket expenses as % of Healthcare expenditure
over FY16-20E and is expected to reach INR 7.3trn by fiscal 2024 63%
Private Government
51% 51%
9% 45%
Healthcare 27% 35% 35%
Delivery 31%
20% 28%
FY20E:
Domestic 17%
INR 4.3 trn 71% 73%
Pharmaceuticals 11% 11%

Medical Devices
India Nepal Sri Lanka Vietnam Malaysia Indonesia Singapore Brazil UK Thailand US

India spends too little on its healthcare

Healthcare expenditure as % of GDP Per capital healthcare expenditure (in $)
17% 10,624
4,315

10% 10% 2,824

6% 6%
5%
4% 4% 4% 4% 3% 848
427 276 157 152 112 73 58

US UK Brazil Vietnam Nepal Singapore Thailand Sri Lanka Malaysia India Indonesia US UK Singapore Brazil Malaysia Thailand Sri Lanka Vietnam Indonesia India Nepal

Source: CRISIL research 10

Note: Healthcare expenditure data as of 2018; Per-capita data at an international dollar rate, adjusted for purchasing-power parity
LARGE MARKET WITH STRONG GROWTH PROSPECTS
India lags behind other developed and emerging economies in Deaths due to disease is higher while healthcare infrastructure is
healthcare infrastructure poor
Beds per 10,000 people India’s share as percentage to world
81

43 Global median: 29
29 26 25 21 21 19 No. of Deaths 17%
12

Russia China US Vietnam UK Thailand Brazil Malaysia India

Physicians per 10,000 people
28 26 Beds 7%
23 22
20
15 Global average: 16
9 8 8
4
Physicians 10%
UK US Singapore Brazil China Malaysia India Thailand Nepal Indonesia
Nurses per 10,000 people
146
101
82 Global average: 38 Nurses & Midwives 8%
62
35 31 27 24 17
28

US Brazil UK Singapore Malaysia Nepal Thailand China Indonesia India

Source: CRISIL research 11
Note: India bed density is estimated by CRISIL Research; Bed Density data as of 2017; Annual no. of deaths in India (2017) caused due to disease have been considered as compared to that of the world
RAPID DEMAND GROWTH DRIVEN BY DEMOGRAPHIC SHIFTS,
CHANGING CONSUMPTION PATTERNS, INCREASING AFFORDABILITY
AND FAVORABLE REGULATORY ENVIRONMENT
Non-communicable disease accounts for most number of deaths Population in 60+ age group to grow faster
Causes of death in India 0-14 years 14-29 years 30-44 years 45-59 years 60+ years
Communicable diseases Cancer
Cardiovascular diseases Other non-communicable diseases
Others 9% 10% 13%
11% 11%
13% 16% 16%
26% 28% 21% 23% 24%
28%
32% 30% 26% 24%
8%
12%
28% 27% 26% 23%
16%

2016 2030P 2016E 2021P 2026P

Growing health insurance penetration to propel demand Pradhan Mantri Jan Arogya Yojana adds a demand impetus
Population-wise distribution amongst various insurance business (million)
36%
28% Individual business

17% Group (other than

357 Govt business) ~23,289 ~10mm INR 13,412cr ~125mm
273 Government Hospitals Treatments Claims worth Cards
161 sponsered schemes empanelled
57 73 Coverage
30 21 29 42
FY12 FY16 FY19 Strategic partnerships to spread awareness, technology partnership and industry
Higher health insurance penetration allows greater access to quality healthcare partnerships
12
Source: CRISIL research
INDIA OFFERS SIGNIFICANT OPPORTUNITY FOR GROWTH OF
MEDICAL TOURISM
India is fast emerging as a major medical tourist destination
Medical tourists (in mn) 0.69
Medical tourism market in India to rise at a CAGR of 65-
70% between fiscals 2021 and 2025
0.23
0.16

2010 2015 1 2019

Treatments mostly sought after in India are high end
~63% of medical tourism demand from neighboring countries treatments pertaining to complex ailments like heart
Break-up of medical tourists by major regions of origin
surgery, knee implant, cosmetic surgery and dental care,
Others due to the low costs of treatments in India
North America 9%
3%
Africa
8% South
2018 Asia Growth in medical tourism expected primarily due to (i)
West Asia 63% Technologically advanced hospitals (ii) highly skilled
17%
doctors; (iii) lower cost of treatment and (iv) e-medical
India enjoys a cost advantage globally with control over quality visas (v) holistic wellness - traditional healthcare therapies
(Ayurveda & Yoga) combined with allopathic treatments
Ailments (US$) US Korea Singapore Thailand India
Hip replacement 50,000 14,120 12,000 7,879 7,000
Knee Replacement 50,000 19,800 13,000 12,297 6,200 Medical tourist from South and West Asia region continue
Heart bypass 144,000 28,900 18,500 15,121 5,200 to constitute majority share
Angioplasty 57,000 15,200 13,000 3,788 3,300
Heart valve replacement 170,000 43,500 12,500 21,212 5,500
Dental implant 2,800 4,200 1,500 3,636 1,000
Source: CRISIL research
13
Note: 1 Includes medical visa and medical attendant visa
OPPORTUNITY FROM INCREASING DIGITAL ADOPTION AIDED BY
FAVORABLE CONSUMER BEHAVIOR AND STRONG IMPETUS
PROVIDED BY COVID
Data driven revolution in the country has led to a generation of digitally inclined consumer…

Robust internet subscribers growth… …and rapid tech adoption

Internet users (in mm)

974
742

302 556 911 ~60%

FY20E FY25P Smartphone
FY15 FY20E FY25P penetration by
4G &5G subscriber base in India
(mm) 2022
… which has been further driven by Covid
No. of people using online No. of users using e-
Healthcare delivery witnessing an influx of mobile-based health consultations pharmacy website/apps
applications

Growth in demand for telemedicine and e-pharmacy

~3 times 2.5-3 times
between March to between March and
Movement towards low touch healthcare model
November 2020 June 2020

Source: CRISIL research

14
03 EXCELLENCE IN PRACTICE

15
 QUALITY HEALTHCARE SERVICES DELIVERY ON THE BACK OF
WORLD-CLASS CLINICAL EXCELLENCE
Leaders in clinical quality & excellence – 8 hospitals received JCI accreditations & 321 hospitals NABH accreditations

Significant contribution (60%) from high-end tertiary care practice2

 35 Units  36 Units
 10,000+ heart surgeries in FY20  35,000+ Neuro surgical discharges in FY20 Cardiology
21%

Others
40%

 22 Units with Medical & Surgical  24 Units Oncology

Oncology  ~1,400 Solid Organ transplant in FY20 11%
 12 Units with Medical, Surgical and
Radiation Oncology

Neuro Sciences
12%
 39 Units  38 Units Gastroenterology
6% Orthopaedic
 6,500+ Joint replacements in FY20  200,000+ footfalls annually 10%
Key differentiating factors for Centers of Excellence

Safety
through Clinical Academics &
Experience Expertise
system & outcomes Research
protocols

Note: Data as of Mar 31, 2020. FY21 will not be an appropriate representation due to COVID-19.1accreditations as of FY21.
16
2In-Patient revenue contribution + Out-Patient revenue of Radiation & Chemotherapy
PIONEERS IN TECHNOLOGY ADOPTION
One of the first to adopt robotics precision in minimally invasive surgery

2014 2019 2020

Eleven robotic surgical Proton Beam Therapy, an
3.0 Magnetic resonance One Prism 640 slice dynamic
systems that enables robotic advanced form of radiotherapy
imaging (“MRI”) system, an multi-detector CT scanner, an
precision in minimally invasive
advanced diagnostic imaging advanced diagnostic tool used
surgery
system which produces three in heart, brain and whole body
dimensional images scanning

Since its inception, Apollo Hospitals has actively invested and strived to embrace advanced medical technology

SERVICE EXCELLENCE – THE MINTMARK OF APOLLO

Voice Of Customer  Mainstream Software enabled feedback collection framework Tender Loving Care  Motto of the organization & Follow the concept of ADCA

Apollo Instant  Tool for collecting feedback given by patient/attender at the  Monthly review mechanism for Key Service Excellence
point of service SE@29 Review
Feedback System Initiatives

Centralized Post  Initiative to reach out to patients post discharge within 72

Discharge hours Patient satisfaction
 Reduction of wait time during in-patient discharge
projects
 An inpatient non-clinical software enabled assist system to
Dial 30
address the non-clinical needs of our patient/attender
17
 SUPERIOR OPERATING &
04 FINANCIAL TRACK RECORD

18
STRONG GROWTH IN REVENUES ACROSS BUSINESSES …

Total Consolidated Revenues (1) (` Mn) FY 21 Consolidated Consolidated Revenues

FY 21 Numbers impacted by COVID-19 pandemic
Revenues of $ 1.5 billion (2) CAGR (FY13-21) of 14%.
(1) Revenue is net of fees paid to fee-for-service consultants in Hospitals
(2) Revenues of Kolkata, Delhi & Lucknow (till Dec-20) are not consolidated under Ind AS due to joint control
Others segment above includes AHLL & Apollo Munich till FY15 and post that only AHLL as Apollo Munich is not consolidated.
Source: Company audited financials Healthcare services
57,297 including AHLL** Revenue
51,426
45,157
48,206 50,222 CAGR (FY13-21) of 10%
40,851 38,860
37,033 48,760*
32,214 32,689 Standalone Pharmacies
28,843 27,852
22,243
25,572
23,220 Revenue CAGR (FY13-21)
19,112 17,726 of 20%.
15,209
12,671
8,606 11,017 13,648
3,343 4,850 6,614 6,964 6,818
3,854 4,589 5,888
205 328 626 1,098 1,351 1,845 1,894
127
FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY 20 FY 21
Healthcare services SAP Others
*includes SAP from 1st April to 31st Aug 20 & Pharmacy Distribution from 1st Sep 20
**AHLL – Apollo Health and Lifestlye Ltd
19
… AIDED BY STRONG OPERATING METRICS (1/2)

Operational Highlights

Occupancy rates remain Average length of stay Average revenue per

high despite bed (ALOS) has reduced across occupied bed (ARPOB) has
additions the portfolio grown at a healthy CAGR of
• Growth of in-patient • Reduced in mature 8% over the last 11 years
volumes in line with hospitals due to • Culmination of high
addition of beds advancement in occupancy, higher
• New hospitals are treatments realizations, better case
ramping up well • Increase in minimally – mix & decreasing ALOS
invasive procedures

• Steady growth of In-patient • Consistent reduction in ALOS • Average Revenue per Occupied
admissions from 235,000 in FY10 from 4.84 days in FY10 to 3.86 Bed has a healthy CAGR of 8% for
to 352,000 in FY21(pandemic days in FY20 the last eleven years
year), CAGR of 4% * FY21 ALOS of 4.19 days due to
* Pre-pandemic CAGR – 7% COVID admissions. 20
… AIDED BY STRONG OPERATING METRICS (2/2)
FY 21 Numbers impacted by COVID-19 pandemic
Bed Occupancy Rate(1) %
In-patient Admissions (‘000)
Operating Beds
478
399 428 451 3,930 4,257 4,767(2) 5,153(2) 5,549(2)5,811(2) 6,321 6,724 6,940 7,111 7,246 7,491 7,409
374
281 313 332 354 352
76% 73% 73% 71% 72% 71% 68%
265
211 235 63% 64% 66% 68% 67%
55%

FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21

FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21
Average Length of Stay (Days)(3) Average Revenue Per Occupied Bed(4) ARPOB (`/Day)
5.15 4.84 4.79 4.78
4.65 4.54 4.43 4.17
4.06 3.99 3.99 3.86 4.19
40,214
37,397
34,226
31,967
29,867 31,377

21,724 23,684 25,381

FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 18,474 20,455
15,184 16,620
Note: All operating data for owned hospitals.
(1) Bed Occupancy Rate: Total Occupied Bed Days/Total Operating Bed Days.
Represents % of available hospital beds occupied by patients.
(2) Excludes our hospitals located outside India.
(3) ALOS represents average number of days patients stay in our hospitals.
(4) ARPOB (Net of doctor fees): Total Hospital Revenue/Patient Days (Total
Occupancy in Numbers (Average Daily Census) x No of days). FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21
Source: Company MIS reports 21
… RESULTING IN CONSISTENT PROFITABILITY
FY 21 Numbers impacted by COVID-19 pandemic

Segment wise EBITDA Margins (%)

Mature Hospitals EBITDA target of 23%-24% over
22% 23% 24% 24% 23%
20% 21% 22% 21% 21% 21% 21% the next 3 years.
14%

7% 8% 8% *
5% 6% 6%
3% 3% 3% 4% 5%
0%
2% 3% 2% 14 New hospitals including Proton with 2,800+
beds (2,100 operational beds) added in the last
FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY17 FY18 FY19 FY20 FY21 few years with $490 mn of Capital employed will
-2% -4% -1% contribute meaningfully to EBITDA over the next
-5% -7%
Existing Healthcare services New Healthcare services SAP 3-4 years.
Consolidated reported EBITDA includes 3 separate businesses with different margin
profiles; Healthcare Services (50% of total Revenues), Standalone Pharmacies (44% of
total Revenues) and Retail Healthcare (AHLL) (6%).
AHLL which represents the Company’s foray into
Retail Healthcare business with AHEL investment
of over $ 60 mn expected to yield returns over
the next 2-3 years driven primarily through
Source: Company audited financials expansion of Diagnostics and Clinics.
*includes : SAP from 1st Apr 20 to 31st Aug 20 and Pharmacy Distribution from 1st Sep 20
22
… AND HEALTHY RETURN ON INVESTMENT
FY 21 Numbers impacted by COVID-19 pandemic
#
ROCE - Mature Healthcare Services (%) 24% 27%
20% 20% 20%
17% 15% 19% 18% 19% 18% 18%
12%
Steady Improvement in Return on Capital Employed (ROCE)

Efficiency
(Asset Turnover) Profitability FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY18 FY 19 FY20 FY 21
ROCE of healthcare services excludes new hospitals (Vanagaram, Jayanagar, Trichy, Nashik, Karapakkam,
Nellore, OMR, Vizag new, Malleswaram, Navi Mumbai, Indore, Assam, Lucknow) as their contribution to EBIT is
Efficient use of capital Higher revenue & yet to be realised. New hospitals Capital employed of Rs 31,243 mn as of Mar 21.
• Strong project profitability ROCE - Standalone Pharmacy (%) 51%
execution • Balanced out-
capabilities patient & in-
• Right mix of beds & 01 ROCE 02 patient mix 19%
24%
medical 15%
• Reduced ALOS 6% 10% 7% 9% 15%
infrastructure • Increasing ARPOB 0% 0% 3%
• Higher utilization of • Improving case
key facilities & mix FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY20 FY21
equipments # Includes New Hospitals Investments
• Quick ramp up of ROCE - Consolidated (%)
13% 13% 14% 14% 12% 14% *
new hospitals— 12%
increasing patient 10% 10%
flow & occupancy 8% 7% 8% 8%

Source: Company audited financials FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY20 FY21

* FY 21 ROCE (excluding capital employed of New Hospitals and Clinics) is at 21%
# Excludes CWIP & Investments in liquid mutual funds 23
STANDALONE PHARMACIES: CAPTURING THE GROWTH POTENTIAL
Proven ability to expand the store network
4,118
• India’s largest Organized Pharmacy Chain with 3,021
3,428
3,766
Pharmacy
presence in ~400 cities/ towns spread across 20 2,326
2,556
store
1,632 1,822
States and 4 union territories. 883 1,049
1,199 1,364 1,503 ramp up
617

• 4,118 Operating Stores as on 31st Mar 2021.

FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21

• Employee Strength of 30,000 people serving ~ Well established track record of growth 48,206 *48,760
300,000 customers 24 X 7 everyday 32,689
38,860
28,745
23,237
• Consistent growth in Revenues & EBITDA 8,606 11,017
13,648
17,725 Revenues
1,996 3,322 4,817
6,614 (` Mn)
improvement.
FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21
• Own brand private labels (FMCG & OTC drugs) 6.0% 6.0%
constitutes over 9% of turnover. Strong profit margins
2,893 * 2,937

5.2%
CAGR (FY11-21): 58%
• Attractive, best-in-class ROCE at 51% (FY21) 4.5% 2,031
4.3%
1,479
3.5% 1,233 EBITDA
3.3%
3.3% 803 (` Mn)
-5.5% -2.0% 0.5% 1.9% 2.7% 580
-89
-183 293
449 & Margins
-4.5% -94 164
31

Source: Company audited financials and MIS reports FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 24
* FY21 includes SAP from 1st Apr 20 to 31st Aug 20 and Pharmacy distribution from 1st Sep 20
 FY21: FINANCIAL PERFORMANCE (1/7)
Standalone Financials (` Mn) Consolidated Financials (` Mn)
FY 20 FY 21 yoy (%) FY 20 FY 21 yoy (%)
Revenue 97,944 91,530 -6.5% Total Revenues 112,468 105,600 -6.1%
Operative Expenses 51,820 53,574 3.4% EBITDA (Pre Ind AS 116) 12,880 9,122 -29.2%
Employee Expenses 15,192 12,751 -16.1% margin (%) 11.45% 8.64% -281 bps
Administrative & Other Expenses 16,780 15,731 -6.3% EBITDA (Post Ind AS 116) 15,873 11,374 -28.3%
Total Expenses 83,792 82,056 -2.1% margin (%) 14.11% 10.77% -334 bps
EBITDA (Pre Ind AS 116) 11,894 7,988 -32.8% EBIT 9,676 5,643 -41.7%
margin (%) 12.14% 8.73% -342 bps margin (%) 8.60% 5.34% -326 bps
EBITDA (Post Ind AS 116) 14,152 9,474 -33.1% Profit After Tax 4,549 1,504 -66.9%
margin (%) 14.45% 10.35% -410 bps
Total Debt 28,596
Depreciation 4823 4359 -9.6% Cash & Cash equivalents (includes
EBIT 9,330 5,115 -45.2% 17,222
investment in liquid funds)
margin (%) 9.53% 5.59% -394 bps Net Debt 11,374
Financial Expenses 4259 3438 -19.3%
Other Income 109 182 66.2%
Exceptional item* 1644 -91
Profit Before Tax 6824 1767 -74.1%
Profit After Tax 4,703 1,052 -77.6%
margin (%) 4.80% 1.15% -365 bps

Total Debt 22,815

Cash & Cash equivalents (includes
13,594
investment in liquid funds)
Net Debt 9,221

25
Q4 FY 21 : SEGMENT-WISE PERFORMANCE (2/7)
Standalone Financials (` mn)
Healthcare Service Healthcare Services Pharmacy
New Hospitals Proton Standalone
(Mature) (Total) Distribution
Hospitals 21 10 1 32
Operating beds 3,163 1,563 53 4,779
Occupancy 63% 57% 35% 61%
Revenue 9,407 3,197 309 12,913 11,187 24,101
EBITDA (Pre Ind AS 116)* 2,167 437 7 2,611 793 3,405
margin (%) 23.0% 13.7% 2.4% 20.2% 7.1% 14.1%
Q4 FY 21 24/7 Operating Costs -252 -252
EBITDA (Pre Ind AS 116) 2,167 437 7 2,611 541 3,153
margin (%) 23.0% 13.7% 2.4% 20.2% 4.8% 13.1%
EBITDA (Post Ind AS 116) 2,273 500 25 2,799 559 3,358
margin (%) 24.2% 15.7% 8.1% 21.7% 5.0% 13.9%
EBIT 1,683 234 -74 1,843 501 2,344
margin (%) 17.9% 7.3% -24.0% 14.3% 4.5% 9.7%
Hospitals 22 10 1 33
Operating beds 3,359 1,489 47 4,895
Occupancy 63% 58% 30% 61%
Revenue 9,187 2,752 197 12,136 13,585 25,721
EBITDA (Pre Ind AS 116) 1,954 166 -90 2,030 847 2,877
Q4 FY 20
margin (%) 21.3% 6.0% 16.7% 6.2% 11.2%
EBITDA (Post Ind AS 116) 2,054 230 -75 2,210 1,274 3,483
margin (%) 22.4% 8.4% 18.2% 9.4% 13.5%
EBIT 1,521 -30 -156 1,335 858 2,193
margin (%) 16.6% 11.0% 6.3% 8.5%
YOY Growth
Revenue Growth 2.4% 16.2% 6.4% -17.7% -6.3%
EBITDA (Pre Ind AS 116)* Growth -6.3% 18.3%
EBITDA (Pre Ind AS 116) Growth 10.9% 162.8% 28.6% -36.1% 9.6%
EBITDA (Post Ind AS 116) Growth 10.7% 117.6% 26.7% -56.1% -3.6%
EBIT Growth 10.7% 38.1% -41.6% 6.9%
26
*EBITDA Pre Ind AS 116 - excluding 24/7 operating costs
FY 21: SEGMENT-WISE PERFORMANCE (3/7)
Standalone Financials (` mn)
Healthcare Service Healthcare Services * Pharmacy
New Hospitals Proton Standalone
(Mature) (Total) Distribution
Hospitals 21 10 1 32
Operating beds 3,163 1,563 53 4,779
Occupancy 52% 54% 35% 53%
Revenue 30,663 11,125 982 42,770 48,760 91,530
EBITDA (Pre Ind AS 116)** 4,321 810 -80 5,051 3,189 8,240
margin (%) 14.1% 7.3% 11.8% 6.5% 9.0%
FY 21 24/7 Operating Costs -252 -252
EBITDA (Pre Ind AS 116) 4,321 810 -80 5,051 2,937 7,988
margin (%) 14.1% 7.3% -8.2% 11.8% 6.0% 8.7%
EBITDA (Post Ind AS 116) 4,740 1065 -11 5,794 3680 9,474
margin (%) 15.5% 9.6% -1.2% 13.5% 7.5% 10.4%
EBIT 2,594 9 -393 2,210 2904 5,115
margin (%) 8.5% 0.1% 5.2% 6.0% 5.6%
Hospitals 22 10 1 33
Operating beds 3,359 1,489 47 4,895
Occupancy 67% 62% 24% 65%
Revenue 38,061 11,091 586 49,738 48,206 97,944
EBITDA (Pre Ind AS 116) 8,357 917 -273 9,001 2,893 11,894
FY20
margin (%) 22.0% 8.3% 18.1% 6.0% 12.1%
EBITDA (Post Ind AS 116) 8,755 1,169 -224 9,700 4,452 14,152
margin (%) 23.0% 10.5% 19.5% 9.2% 14.4%
EBIT 6,767 128 -468 6,428 2902 9,330
margin (%) 17.8% 12.9% 6.0% 9.5%
YOY Growth
Revenue Growth -19.4% 0.3% 67.6% -14.0% 1.1% -6.5%
EBITDA (Pre Ind AS 116) ** Growth 10.2% -30.7%
EBITDA (Pre Ind AS 116) Growth -48.3% -11.7% -43.9% 1.5% -32.8%
EBITDA (Post Ind AS 116) Growth -45.9% -8.9% -40.3% -17.3% -33.1%
EBIT Growth -61.7% -92.9% -65.6% 0.1% -45.2%
*includes SAP from 1st Apr 20 to 31st Aug 20 and Pharmacy Distribution from 1st Sep 20 27
**EBITDA Pre Ind AS 116 - excluding 24/7 operating costs
Q4 FY 21 : SEGMENT-WISE PERFORMANCE (4/7)
Consolidated Financials (` mn)
Healthcare Serv
Healthcare Serv Healthcare Serv Pharmacy
Group (New & Proton AHLL Consol
Group (Mature) Group (Total) Distribution
Others)
Hospitals 30 13 1 44
Operating beds 5,290 2,066 53 7,409
Occupancy 64% 60% 35% 63%
Revenue 10,597 4,481 309 15,388 11,187 2,105 28,680
EBITDA (Pre Ind AS 116)** 2,442 600 7 3,049 793 127 3,970
margin (%) 23.0% 13.4% 2.4% 19.8% 7.1% 6.0% 13.8%
Q4 FY 21 24/7 Operating Costs -252 -252
EBITDA (Pre Ind AS 116) 2,442 600 7 3,049 541 127 3,718
margin (%) 23.0% 13.4% 2.4% 19.8% 4.8% 6.0% 13.0%
EBITDA (Post Ind AS 116) 2,552 677 25 3,254 559 305 4,118
margin (%) 24.1% 15.1% 8.1% 21.1% 5.0% 14.5% 14.4%
EBIT 1,895 335 -74 2,155 501 77 2,734
margin (%) 17.9% 0.0% 0.0% 14.0% 4.5% 3.7% 9.5%
Hospitals 31 13 1 45
Operating beds 5,489 1,955 47 7,491
Occupancy 64% 61% 30% 63%
Revenue 10,325 3,444 197 13,966 13,585 1,673 29,224
EBITDA (Pre Ind AS 116) 2,052 196 -90 2,159 847 -17 2,989
Q4 FY 20
margin (%) 19.9% 5.7% 15.5% 6.2% -1.0% 10.2%
EBITDA (Post Ind AS 116) 2,165 273 -75 2,363 1,274 164 3,801
margin (%) 21.0% 7.9% -37.9% 16.9% 9.4% 13.0%
EBIT 1,556 -30 -156 1,370 858 -66 2,162
margin (%) 15.1% 9.8% 6.3% -3.9% 7.4%
YOY Growth
Revenue Growth 2.6% 30.1% 10.2% -17.7% 25.8% -1.9%
EBITDA (Pre Ind AS 116)* Growth -6.3% 32.8%
EBITDA (Pre Ind AS 116) Growth 19.0% 205.3% 41.3% -36.1% 24.4%
EBITDA (Post Ind AS 116) Growth 17.9% 148.2% 0.0% -56.1% 86.1% 8.4%
EBIT Growth 21.8% 57.3% -41.6% 26.5%
*EBITDA Pre Ind AS 116 - excluding 24/7 operating costs 28
 FY21: SEGMENT-WISE PERFORMANCE (5/7)
Consolidated Financials (` mn)
Healthcare Serv
Healthcare Serv Healthcare Serv * Pharmacy
Group (New & Proton AHLL Consol
Group (Mature) Group (Total) Distribution
Others)
Hospitals 30 13 1 44
Operating beds 5,290 2,066 53 7,409
Occupancy 54% 57% 35% 55%
Revenue 34,682 14,358 982 50,022 48,760 6,818 105,600
EBITDA (Pre Ind AS 116)** 5,016 1,152 -80 6,087 3,189 98 9,374
margin (%) 14.5% 8.0% -8.2% 12.2% 6.5% 1.4% 8.9%
FY 21 24/7 Operating Costs -252 -252
EBITDA (Pre Ind AS 116) 5,016 1152 -80 6,087 2,937 98 9,122
margin (%) 14.5% 8.0% 12.2% 6.0% 1.4% 8.6%
EBITDA (Post Ind AS 116) 5,480 1,457 -11 6,925 3,680 768 11,374
margin (%) 15.8% 10.1% 13.8% 7.5% 11.3% 10.8%
EBIT 3,026 213 -393 2,845 2904 -107 5,643
margin (%) 8.7% 1.5% 5.7% 6.0% 5.3%
Hospitals 31 13 1 45
Operating beds 5,489 1,955 47 7,491
Occupancy 69% 64% 24% 67%
Revenue 42,892 13,820 586 57,297 48,206 6,964 112,468
EBITDA (Pre Ind AS 116) 9,189 1,054 -273 9,970 2,893 18 12,880
FY 20
margin (%) 21.4% 7.6% 17.4% 6.0% 0.3% 11.5%
EBITDA (Post Ind AS 116) 9,629 1,346 -224 10,750 4,452 671 15,873
margin (%) 22.4% 9.7% 18.8% 9.2% 9.6% 14.1%
EBIT 7,295 166 -468 6,993 2,902 -219 9,676
margin (%) 17.0% 1.2% 12.2% 6.0% -3.1% 8.6%
YOY Growth
Revenue Growth -19.1% 3.9% -12.7% 1.1% -2.1% -6.1%
EBITDA (Pre Ind AS 116) ** Growth 10.2% -27.2%
EBITDA (Pre Ind AS 116) Growth -45.4% 9.3% -38.9% 1.5% -29.2%
EBITDA (Post Ind AS 116) Growth -43.1% 8.3% -35.6% -17.3% -28.3%
EBIT Growth -58.5% 28.3% -59.3% 0.1% -41.7%
*includes SAP from 1st Apr 20 to 31st Aug 20 and Pharmacy distribution from 1st Sep 20 29
**EBITDA Pre Ind AS 116 - excluding 24/7 operating costs
FY21: HOSPITAL CLUSTER - WISE OPERATIONAL PERFORMANCE
(6/7)
Tamilnadu Region AP, Telengana Region
Total (8) (1)
(Chennai & others) (Hyderabad & others) (2)
Particulars FY 20 FY 21 yoy (%) FY 20 FY 21 yoy (%) FY 20 FY 21 yoy (%)
No. of Operating beds 7,491 7,409 2,208 2,043 1,344 1,344
Inpatient volume 478,032 352,624 -26.2% 134,713 85,403 -36.6% 78,002 50,151 -35.7%
(6)
Outpatient volume 1,627,514 1,160,247 -28.7% 531,218 311,329 -41.4% 238,382 167,513 -29.7%
Inpatient ALOS (days) 3.86 4.19 3.53 4.20 3.90 4.48
Bed Occupancy Rate (%) 67% 55% 59% 48% 62% 46%
Inpatient revenue (` mio) NA NA 16,660 14,252 -14.5% 9,159 8,761 -4.3%
Outpatient revenue (` mio) NA NA 5,742 3,348 -41.7% 1,840 1,685 -8.5%
ARPOB (` /day) (7) 37,397 40,214 7.5% 47,151 49,115 4.2% 36,184 46,479 28.4%
(7)
Total Net Revenue (` mio) NA NA 22,402 17,600 -21.4% 10,999 10,445 -5.0%

Notes:
(1) Tamilnadu region includes Chennai hospitals, Madurai, Karur, Karaikudi, Trichy & Nellore.
(2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada.
(3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram.
(4) Others include Bhubaneswar, Bilaspur, Nashik & Navi Mumbai.
(5) Significant Hospital JVs/Subs/Associates are – Ahmedabad, Kolkata, Delhi, Indore, Assam & Lucknow (full revenues shown in table above).
(6) Outpatient volume represents New Registrations only.
(7) Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP.
(8) Revenues under the head “Total” have not been provided as Consolidated actual results will differ from total. Revenues from JVs & Associates are not consolidated under Ind AS.
* Inpatient volumes are based on discharges.

30
FY 21: HOSPITAL CLUSTER - WISE OPERATIONAL
PERFORMANCE (7/7)
Karnataka Region
Others (4) Significant Subs/JVs/associates (5)
(Bangalore & others) (3)
Particulars FY 20 FY 21 yoy (%) FY 20 FY 21 yoy (%) FY 20 FY 21 yoy (%)
No. of Operating beds 769 769 962 1,011 2,208 2,242
Inpatient volume 55,881 45,392 -18.8% 71,940 62,297 -13.4% 137,496 109,381 -20.4%
(6)
Outpatient volume 179,906 166,271 -7.6% 145,473 138,304 -4.9% 532,535 376,830 -29.2%
Inpatient ALOS (days) 3.61 3.79 4.00 4.00 4.21 4.32
Bed Occupancy Rate (%) 72% 61% 82% 67% 72% 58%
Inpatient revenue (` mio) 6,204 5,410 -12.8% 6,288 6,191 -1.5% 16,585 14,368 -13.4%
Outpatient revenue (` mio) 1,126 1,035 -8.1% 1,125 1,009 -10.3% 3,738 2,836 -24.1%
ARPOB (` /day) (7) 36,336 37,463 3.1% 25,790 28,919 12.1% 35,145 36,441 3.7%
(7)
Total Net Revenue (` mio) 7,330 6,446 -12.1% 7,413 7,200 -2.9% 20,322 17,204 -15.3%

Notes:
(1) Tamilnadu region includes Chennai hospitals, Madurai, Karur, Karaikudi, Trichy & Nellore.
(2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada.
(3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram.
(4) Others include Bhubaneswar, Bilaspur, Nashik & Navi Mumbai.
(5) Significant Hospital JVs/Subs/Associates are – Ahmedabad, Kolkata, Delhi, Indore, Assam & Lucknow (full revenues shown in table above).
(6) Outpatient volume represents New Registrations only.
(7) Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP.
(8) Revenues under the head “Total” have not been provided as Consolidated actual results will differ from total. Revenues from JVs & Associates are not consolidated under Ind AS.
* Inpatient volumes are based on discharges.

31
 APOLLO HEALTH AND LIFESTYLE – RETAIL HEALTHCARE
Revenue FY21 of INR 6,818 mm – Primary Care (27%), Diagnostics (20%) & Specialty Care (53%)

 Multi specialty clinics that extend Apollo’s expertise to

 Dialysis services, PPP centres in AP, Assam & Bihar
the neighborhood
 69 Centers
 191 Clinics

 B2C focused pathology business; Hub-and-spoke

 Planned specialties surgery centers model, with a focus on South & East India
 15* Centers  796 Centers

 Treatment solutions for Diabetes; long term disease

 Women and children focused hospital
management programs delivered via tech platform
 9* Centers
 22 Clinics

 Pan-India chain, with a combination of stand-alone, in-

 Provides female reproductive medical services
hospital and in-clinic models
 11 Centers
 62 Centers

32
Note: % indicate share of net revenue ; *Includes BOMA (Brand Operations and Management Agreement) Apollo Spectra (4) and Apollo Cradle & Children’s Hospital (1).
05 STRONG MANAGEMENT TEAM

33
APOLLO HAS ALWAYS BEEN AT THE FORE-FRONT OF DEVELOPMENT
OF INDIA'S HEALTHCARE SECTOR
Apollo Impact
 Improved overall availability of
private health care services in India  First in India to obtain international JCI
accreditation
 Better access to care in semi-urban
and rural areas

Enhanced
Improved  Attractive destination for medical talent in
clinical outcomes
geographic access India and from overseas
 Equitable access to health services  Helped India become the destination of
through price differentiation, choice for medical tourists
telemedicine, and CSR initiatives

Improved Impact on
financial access Private healthcare
sector

34
EXECUTIVE BOARD
Dr. Prathap C. Reddy Suneeta Reddy
Executive Chairman, Founder Managing Director
• Conferred the Padma Vibhushan in 2010 • On the Board since the year 2000
• Conferred the Padma Bhushan in 1991
• Spent 36 years with Apollo Hospitals

Dr. Preetha Reddy Sangita Reddy

Executive Vice Chairperson Joint Managing Director
• On the Board since the year 1989 • On the Board since 2000
• 30+ years healthcare experience

Shobana Kamineni
Executive Vice Chairperson
• On the Board since 2010

35
INDEPENDENT DIRECTORS
Vinayak Chatterjee Bhaskara Mandavilli Nageswara Rao
Independent Director Independent Director
• On the Board since 2014 • On the Board since Feb 2019

Dr. Rajgopal Thirumalai Velagapudi Kavitha Dutt

Independent Director Independent Director
• On the Board since May 2017 • On the Board since Feb 2019

Dr. Pudugramam Murali Doraiswamy

Independent Director
• On the Board since Sep 2018

Note: Data as of Mar 31, 2021 36

 STRATEGY FOR FUTURE
06 GROWTH

37
STRATEGY FOR FUTURE GROWTH (1/2)
Strategy

 Optimise Asset Utilisation in facilities & locations

30 5,954  Focus on Centers of Excellence with one or two anchor specialties in each
Hospitals1 Capacity market
Mature Beds
Hospitals  Extend and expand oncology presence both through specialization and
exclusive oncology referral hospitals in the cluster
5,290 54%
Operational Beds Occupancy rate  Cost Efficiencies & Focus on Improving Key Operating Metrics

 Onboard clinical talent with subspecialty expertise.

 Strengthen presence and increase market share in key strategic markets

14 2,862  Recruit relevant local medical talent and introduce newer technology to
Hospitals1 Capacity augment clinical offerings
New Beds
Hospitals

2,119 57%
Operational Beds Occupancy rate

Note: Data as of Mar31, 2021; Internally company classifies any hospital commissioned prior to 9 years as mature hospital; 1 Corresponds to owned hospitals only 38
STRATEGY FOR FUTURE GROWTH (2/2)
Strategy
 Focus on urban markets; expand in clusters

 Owned clinic models in metros, franchisee clinics in Tier II towns

Apollo Health
1140 35*
& Lifestyle Primary care Specialty
(AHLL) centers care centers

 Derive economies of scale that arise from the largest pharmacy chain

Strong  Exclusive supplier to APL and license “Apollo Pharmacy” brand

4,118
Outlets distribution
Pharmacies  Enhance Private label business and focus on high prescription fulfilment
platform rates

Asset light Robust  Data-driven store expansion and Foray into Digital commerce
model supply chain

Note: Data as of Mar 31, 2021; *Includes BOMA (Brand Operations and Management Agreement) Apollo Spectra (4) and Apollo Cradle & Children’s Hospital (1). 39
Apollo HealthCo: Transformational Value Unlocking
Reorganization through Slump Sale
AHEL
• Apollo 24/7 represents Apollo Group’s transformational journey to creating “India’s
(Listed) Largest Omnichannel Digital Healthcare Platform” that:
Backend
Healthcare
Pharmacy + — combines the strengths of Apollo Group’s offline healthcare leadership with Apollo
Services
Apollo 24/7
Group’s new-age digital offerings to address all healthcare consumer needs;
100%
Slump sale
— involves an asset light approach (through digital offerings) to fuel growth – 100
Apollo HealthCo Limited million targeted registered users on Apollo 24/7 platform in 5 years.
(AHL)

— presents huge funnelling potential for healthcare consumers into the Apollo Group
Slump Sale of the identified business undertaking
into AHL including the following ecosystem.

• Back-end pharmacy supply (excludes Hospital • Structure to set the platform for a new pool of investor capital and to enable rapid scale-
Based Pharmacies) up. At the time of capital raise, AHL valuation to reflect current and future growth
potential.
• Apollo 24/7 Digital healthcare Platform
• Post external capital raise at AHL,
• Investment in pharmacy retail business (i.e.
Apollo Medicals Private Limited) — AHEL expected to retain dominant majority shareholding in AHL; and

• “Apollo 24/7” brand, the “Apollo Pharmacy” — Slump sale consideration of INR Rs 1,210 crs will be received by AHEL.
brand and private label brands

40
 APOLLO 24X7 – INDIA’S LARGEST OMNI-CHANNEL HEALTHCARE
PLATFORM LEVERAGING PHYSICAL NETWORK
Distinctive digital ecosystem… … coupled with adequate network and capabilities
Physical network & capabilities
~6.6M+ ~2.9 lakh+ 1 2 3
Registrations Doctors across 3mm+ Annual
Online consults Diagnostic centers
Hospitals & clinics chronic patients
completed
4 5
Leverage from
Corporate tie-ups
30mm+ IP/OP
Apollo
~5,500+
~1.5 Lakh+* 24/7
Doctors Digital services / ecosystem
across
Super & 1 2 3 4
60 Specialties Online medicine Virtual doctor Online diagnostic
Potential Super Offline pharmacy
delivery consultation booking
users Transacting
~6.3 lakh+ 5 6 7 8
Condition Well-being Health insurance
Online Medicine Health predictor
management companion distribution
~30K+ orders delivered
Home Lab Samples 9
collected
AI Doctor Assistant
Differential Diagnosis Clinical Decision Support Lab & Medicine
Unique ecosystem extremely difficult to replicate
Engine system (CDSS) Recommender

Integrated healthcare platform with few parallels globally Integration of digital and physical capabilities provides
Cost efficiencies through sharing of managerial and clinical resources
Best positioned to become the largest digital health platform
Economies of scale & competitive prices through centralized purchasing

30x growth in transactions between Mar’21 and Mar’20 Access to qualified & trained medical resources and larger patient base
41
* Super user: # users with 5 or more completed transactions in 5 consecutive months ; ** Data as on 31st March 21
FUTURE GROWTH STRATEGY – TRANSFORMING THROUGH
TECHNOLOGY AND CLINICAL EXCELLENCE
Integrated digital strategy leveraging existing network, capabilities and market leadership

Focus on investments in advanced technology and innovation –

“(re) Invent the health system of the future”

Asset Light & Bolt on acquisition led expansion strategy in Tier I,

Metros and select Tier II cities in India

Planning for reorganization of the 24/7 platform for better focus

and value unlocking
Apollo
Group’s Focus on high value clinical specialties
Customer
Improve operating efficiencies and profitability

Building deep relationships with the Apollo consumer across

category – hospitals, pharmacy, clinics, diagnostics

Unlocking potential for up-sell, cross-sell, and loyalty driven

behavior using advanced analytics

Focus on Clinical Innovations and outcomes 42

UPDATE ON IMPACT OF COVID-19
 Enhancing protocol driven 40,000+ 20,000+ 8,500+
testing capabilities Inpatients Home care Stay I
 Increasing accessibility
 Ensuring Isolation stays at
medically supervised
accommodations
 Providing support to  Driving Information &
vulnerable patients Awareness
 Encouraging Physical
Screening 1,158 3,99,000+
 Enabling Digital Screening
Dedicated beds Tests
 Ensuring Care Continuum
Clinical preparedness and
cross-sectional training

‘Project Stay I’ saw success with over 78,300 room nights

Home care segment enabled people to move into 51,000 homes, (of which COVID care was at 20,000 homes) and provide medically supervised home
isolation services

Digital healthcare app Apollo 24/7 – agile and digitally connected to the consumer, 5 lakh digital consults till May-21.

Note: Data as of Mar 31, 2021 43

 In summary we have over the last 33 years focused consistently on putting the patient at the core of all that we do in
the pursuit of clinical excellence and in creating sustainable value for our stakeholders. We ensure strict adherence to
business ethics and our governance standards stand exemplar in the industry. With fast changing patient demands,
healthcare for the future is going to require evidence based care delivery through sustained process improvement
driven by standardization of knowledge assets. We are at the forefront of that journey. We will endeavor to leverage
technology proliferation in healthcare to collect, understand and utilize data to improve our care practices. We will
continue to empower the consumer through various on-line mechanisms and make it easy for them to take charge of

THANK YOU
their well being. And we will offer our patients value based care by employing creative approaches for care
distribution—day surgery, specialty clinics and virtual care centres.

We do not operate in isolation, but rather engage deeply with the larger community towards its well being through
several initiatives like SACHi and SAHI which bring healthcare benefits to disadvantaged children and the Billion Hearts
Beating campaign which creates public awareness about cardiac health. Our CSR initiatives are founded on the
conviction we hold close to our hearts—that life and therefore the human body, is priceless, and every man regardless
of his economic background has a right to safeguard it the best way possible. While much still remains to be done, we
take pride that we are working towards creating a healthy tomorrow for generations to come.

44 44